U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. PENMENVY
  1. Vaccines, Blood & Biologics

PENMENVY

STN: BLA 125819 
Proper Name: Meningococcal Groups A, B, C, W, and Y Vaccine
Tradename: PENMENVY
Manufacturer: GlaxoSmithKline Biologicals SA
Indication:

  • PENMENVY is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in individuals 10 through 25 years of age.

Product Information

  • Package Insert - PENMENVY
  • Demographic Subgroup Information – Meningococcal Groups A, B, C, W, and Y Vaccine (PENMENVY)
    Refer to Sections 16.1.4,16.2.1, and 17.1 of the CBER Integrated Review for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.

Supporting Documents

Back to Top